Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 8/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2199381 | 0.87 | CLK4 (0.47) | PDCD1CD274LMNAAPPEPHX2 | |
| SCHEMBL2196713 | 0.87 | BRD4 (0.46) | GAAPDCD1CD274PDE5ABRD4 | |
| SCHEMBL2198386 | 0.85 | PDE5A (0.53) | GAAPDCD1CD274PDE5ABRD4 | |
| SCHEMBL2198508 | 0.84 | BRD4 (0.46) | GAAPDE5ABRD4LMNAAPP | |
| SCHEMBL2197166 | 0.83 | EGFR (0.53) | LMNAKMT2A | |
| SCHEMBL2197333 | 0.82 | PDE5A (0.48) | GAAPDCD1CD274PDE5ABRD4 | |
| SCHEMBL2197416 | 0.80 | EPHX2 (0.45) | PDCD1CD274LMNAEPHX2KMT2A | |
| SCHEMBL2198240 | 0.77 | ALDH1A1 (0.54) | GAAPDCD1CD274PDE5ALMNA | |
| SCHEMBL2198139 | 0.76 | CYP3A4 (0.52) | LMNAAPPKMT2A | |
| SCHEMBL2199265 | 0.75 | CLK4 (0.51) | BRD4LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977360-B2 | Benzo[d]isoxazol-3-yl-amine compounds and their use as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2011-07-12 | — | — | US | claimed |
| EP-1888541-B1 | BENZO(D)ISOXAZOL-3-YL-AMINE COMPOUNDS AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GRUENENTHAL GMBH (DE) | 2009-08-05 | — | — | EP | claimed |
| US-20090042945-A1 | Benzo[d]isoxazol-3-yl-amine Compounds and Their Use as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2009-02-12 | — | — | US | claimed |
| EP-1888541-A1 | BENZO(D)ISOXAZOL-3-YL-AMINE COMPOUNDS AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2008-02-20 | — | — | EP | claimed |
| WO-2006122799-A1 | BENZO(D)ISOXAZOL-3-YL-AMINE COMPOUNDS AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | claimed |
| US-7977360-B2 | Benzo[d]isoxazol-3-yl-amine compounds and their use as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2011-07-12 | — | — | US | disclosed |
| EP-1888541-B1 | BENZO(D)ISOXAZOL-3-YL-AMINE COMPOUNDS AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GRUENENTHAL GMBH (DE) | 2009-08-05 | — | — | EP | disclosed |
| US-20090042945-A1 | Benzo[d]isoxazol-3-yl-amine Compounds and Their Use as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2009-02-12 | — | — | US | disclosed |
| EP-1888541-A1 | BENZO(D)ISOXAZOL-3-YL-AMINE COMPOUNDS AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006122799-A1 | BENZO(D)ISOXAZOL-3-YL-AMINE COMPOUNDS AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042945-A1 | Benzo[d]isoxazol-3-yl-amine Compounds and Their Use as Vanilloid Receptor Ligands | TRPV1, TRPV3, TRPV5 | GAA 2357/4885PDCD1 3916/4885CD274 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.